Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review

Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review

Introduction: Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the impact of VMAT2 inhibitor treatment on patient social and physical well-being. The study objective was...

Full description

Bibliographic Details
Main Authors: Meyer Jonathan M. MD, Chepke Craig MD, Bera Rimal B. MD, Pérez-Rodríguez M. Mercedes MD, PhD, Lundt Leslie MD, Franey Ericha G. PhD, Dhanda Rahul PhD, MA, Benning Betsy MBA, Bron Morgan PharmD, MS, Yonan Chuck PharmD
Format: Article
Language:English
Published: American Association of Psychiatric Pharmacists 2023-10-01
Series:Mental Health Clinician
Subjects:
tardive dyskinesia
valbenazine
deutetrabenazine
tetrabenazine
vesicular monoamine transport inhibitors
antipsychotics
psychiatric diseases
disease burden
patient awareness
patient-centric outcomes
Online Access:https://theijpt.org/doi/pdf/10.9740/mhc.2023.10.225

Internet

https://theijpt.org/doi/pdf/10.9740/mhc.2023.10.225

Similar Items